Portolan Capital Management, LLC

Position in TLX — Telix Pharmaceuticals Ltd

CIK 1350290 BOSTON, MA

Position in TLX

as of Jun 30, 2026 · filed Aug 14, 2026 Compact

Position Value

$293,138

-$4,886,787 QoQ

Shares Held

25,424

-95.3% QoQ

Ownership

0.007%

of shares outstanding

% of Portfolio

0.01%

of 13F equity value

Holder Rank

#25

of 62 holders

Holding Since

Mar 2026

2 quarters on record

Voting authority Sole 100% Shared 0% None 0%

Healthcare · as of Jun 30, 2026

Portolan Capital Management, LLC holds $46,223,505 across 3 Biotechnology names. TLX ranks #3 (0.6% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	CADL	Candel Therapeutics, Inc.	3,490,398	$35,951,099
2	HALO	Halozyme Therapeutics, Inc.	127,498	$9,979,268
3	TLX	Telix Pharmaceuticals Ltd This page	25,424	$293,138

2 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-06-30	$293,138	25,424	-95.3%	Shares	Sole	2026-08-14
2026-03-31	$5,179,925	541,267	—	Shares	Sole	2026-05-15
No filing history on record for this holder in this stock.